[The MDR phenotype in acute nonlymphoid leukemia].
Liso
V
V
Università degli Studi, Bari.
Specchia
G
G
Pansini
N
N
Iacobazzi
A
A
Colucci
A
A
Mininni
D
D
Mestice
A
A
Palumbo
G
G
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000918:Antibody Specificity; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000276:immunology; D004351:Drug Resistance; D005434:Flow Cytometry; D006801:Humans; D007124:Immunoenzyme Techniques; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D008562:Membrane Glycoproteins / Q000032:analysis* / Q000276:immunology; D009363:Neoplasm Proteins / Q000032:analysis* / Q000276:immunology; D010641:Phenotype; D012074:Remission Induction
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins
Fenotipo MDR nelle leucemie acute non linfoidi.